PE-22-28 Peptide: Mechanism, Effects and Availability

Most research peptides that get attention act on growth hormone, tissue repair, or metabolism. PE-22-28 does none of those things. It's a seven-amino-acid fragment aimed at a potassium channel in the brain, and it exists for one blunt reason: the longer peptide it was carved from fell apart in plasma far too quickly to study properly.

We supply research-grade compounds to laboratories, and PE-22-28 generates more confused questions than almost anything else on the neuro side of the catalogue. Roughly half of those questions are about side effects that have never been formally characterised in people. The other half are about what an 8mg vial label actually means.

What is PE-22-28?

PE-22-28 is a seven-amino-acid peptide derived from the propeptide of sortilin and designed as a shortened analog of spadin. In rodent research it acts as an inhibitor of TREK-1, a two-pore-domain potassium channel encoded by the KCNK2 gene and linked to mood regulation. It is supplied strictly for laboratory research and is not an approved drug.

The common over-simplification is that PE-22-28 is just 'smaller spadin' behaving identically. It isn't. Truncating the sequence changed both the reported channel-blocking potency and the metabolic stability profile, which is the entire reason the shortened analogs were synthesised. What follows covers the TREK-1 mechanism, what the rodent work actually reported, the honest state of PE-22-28 side effect data, and how to read an 8mg vial specification before you buy anything.

From sortilin to spadin to a seven-residue fragment

PE-22-28 traces back to a single protein: sortilin, a sorting receptor also known as neurotensin receptor-3. When the enzyme furin cleaves pro-sortilin into its mature form, it releases a propeptide. Researchers at the Institut de Pharmacologie Moléculaire et Cellulaire in France found that a 17-residue stretch of that propeptide, which they named spadin, blocked TREK-1 channels and produced antidepressant-like behaviour in mice. That finding was published in PLoS Biology in 2010.

TREK-1 (also written K2P2.1) is a background potassium channel. When it's open, potassium leaks out of the neuron, holding the membrane at a more negative potential and making the cell harder to fire. Mice genetically lacking TREK-1 show a depression-resistant phenotype, reported by the same research group in Nature Neuroscience. Block the channel and you remove a brake on serotonergic neurons in the dorsal raphe nucleus.

So why PE-22-28 rather than spadin itself? Spadin degrades rapidly in blood, which caps how far a 17-residue peptide can be pushed in vivo. Djillani and colleagues published shortened spadin analogs in Frontiers in Pharmacology in 2017, reporting that the seven-residue version, PE-22-28, inhibited TREK-1 more effectively than the parent peptide while surviving longer in circulation. PE-22-28 is not a reinvention of spadin's mechanism. It's the same target, reached with less molecule.

What the rodent studies report, and what they don't

Here's the detail most descriptions get wrong: the name is a coordinate, not a code. PE refers to the sortilin propeptide, and 22-28 are the residue positions the fragment spans within that propeptide. Spadin is PE 12-28. So PE-22-28 is literally the final seven residues of spadin, nothing more exotic than that. Once you see the naming logic, the sibling analogs (PE 23-28, PE 24-28) make immediate sense as a structure-activity series rather than separate inventions.

The published rodent work reports that shortened spadin analogs reduced immobility in standard behavioural despair paradigms such as the forced swim and tail suspension tests, and that effects appeared over a shorter treatment window than classical SSRIs typically require in the same models. Research also reports increases in markers of hippocampal neurogenesis and synaptogenesis, alongside involvement of the mTOR signalling pathway, which is the same broad territory studied in fast-acting antidepressant research.

What that literature does not contain: human clinical trials, published human pharmacokinetics, chronic toxicology, or any established preparation, administration or use framework. Rodent despair models are screening tools. They flag compounds worth investigating further; they don't forecast human outcomes. Anyone presenting PE-22-28 as a validated antidepressant is describing a mouse result as though it were a clinical one.

We mean this sincerely: the distance between 'active in rodents' and 'useful in humans' is exactly where most promising neuro peptides, including several with better funding than PE-22-28, quietly stop.

Side effects, open questions, and what an 8mg vial tells you

There is no published human side effect profile for PE-22-28. That's the honest answer to the most-searched question about this compound, and any source presenting a tolerability list is extrapolating from animals. Rodent studies of spadin and its shortened analogs reported no gross behavioural toxicity at the quantities tested, and the original research group specifically noted that spadin did not appear to compromise the neuroprotective or seizure-threshold roles TREK-1 also plays. That's encouraging for a screening study. It is not a safety dataset.

The mechanistic caution worth understanding is this: TREK-1 isn't only a mood channel. It participates in neuroprotection during cerebral ischaemia, in pain signalling, and in the response to volatile anaesthetics, all documented in the TREK-1 knockout literature from the same French laboratory. A systemic channel blocker doesn't get to choose which tissue it acts on. That pleiotropy is the real basis for every serious question about PE-22-28 side effects, and it's a large part of why the compound stays research-use-only.

On the label: 8mg describes the mass of lyophilised peptide in the vial. It is not a concentration and it is not an instruction. Net peptide content can differ from gross vial weight because lyophilised material carries counter-ions and residual water, which is why a certificate of analysis showing HPLC purity and mass spectrometry identity confirmation matters more than the number printed on the cap. Everything here is research education. PE-22-28 is supplied for laboratory use only, and if a question about an animal's health brought you here, talk to your veterinarian, because PE-22-28 is not a veterinary product and is not intended for human or animal consumption.

PE-22-28 versus spadin and related TREK-1 tools

Most people evaluating PE-22-28 are really weighing it against spadin or against a reference antidepressant used in the same rodent models. This table summarises what the published literature reports for each, with no efficacy claims attached.

What If: Common Research Handling Scenarios

What if the vial looks empty when it arrives?

Hold it to the light before assuming anything is missing. An 8mg lyophilisation of PE-22-28 frequently forms a thin translucent film or a small puck at the base rather than a visible mound of powder, and shipping vibration can spread that film across the vial wall where it becomes almost invisible. Cross-check the vial against the batch certificate of analysis, which states the gross fill weight for that lot. If the certificate matches the labelled fill, the material is present. Photograph the vial on receipt regardless, because documentation at intake resolves supplier disputes far faster than recollection does.

What if there is no certificate of analysis for the batch?

Treat an uncertified vial as an unidentified compound and don't put it into an experiment. A genuine certificate for PE-22-28 pairs an HPLC chromatogram establishing purity with a mass spectrometry trace confirming molecular weight against the expected seven-residue sequence. Without both, you have a white powder and a claim. Batch-specific documentation also matters more here than with better-known peptides, because the shortened spadin analogs are structurally similar to each other and a sequence error of one residue produces PE 23-28, not PE-22-28, with no visual difference whatsoever.

What if reconstituted material sat at room temperature overnight?

Document the excursion, note it against the experiment, and assume potency is compromised rather than intact. Peptides in aqueous solution are vulnerable to hydrolysis and microbial growth in a way lyophilised powder is not, and short sequences give degradation products that no bench-level visual inspection will reveal. Cloudiness or precipitate is a clear fail signal, but clear solution is not a pass signal. There is no reliable at-home or in-lab shortcut for verifying that reconstituted PE-22-28 retains its original structure short of re-running analytical chemistry on it.

What if a supplier lists preparation, administration or use information alongside the product?

Treat it as a regulatory red flag about the supplier rather than useful information about the compound. PE-22-28 has no established human preparation, administration or use framework because no human study has been published, so any suggested schedule is invented. Legitimate research suppliers state mass, purity, sequence, and storage conditions, then stop. A vendor willing to fabricate a protocol is a vendor with an elastic relationship to accuracy in other areas too, including the analytical data on their certificates.

The honest state of the evidence

Let's be direct about this: PE-22-28 is an interesting rodent result and, right now, nothing more than that. The TREK-1 hypothesis is legitimate, the French work behind it is serious pharmacology, and the mechanism is genuinely distinct from monoamine reuptake drugs. But there are no human trials, no approved formulation, no characterised safety profile, and no regulator anywhere has evaluated PE-22-28 for any purpose. Treating a seven-residue research peptide as a self-directed intervention because a mouse swam longer in a beaker isn't a calculated risk. It's a guess wearing a mechanism as a costume.

Batch documentation for every compound we synthesise is published on our certificates of analysis page, the full research catalogue sits in the shop, and facility and shipping details are on our location page. If TREK-1 work forms part of a wider neuro-research programme, related compounds such as Selank Liquid Spray are synthesised to the same small-batch purity standard.

PE-22-28 is one of the clearest examples in peptide research of a compound whose story is mostly chemistry rather than outcome. Someone looked at a 17-residue peptide that worked in mice and disintegrated in plasma, cut it down to its last seven residues, and got something that blocked the channel harder and lasted longer. That's a real medicinal chemistry achievement. It is also, at this moment, the whole achievement. The channel it blocks remains a hypothesis about depression, and hypotheses don't become therapies until humans are studied, which hasn't happened yet.

How is PE-22-28 purity verified by HPLC and mass spectrometry?

Two orthogonal methods carry most of the weight. Reverse-phase HPLC, usually on a C18 column with a water/acetonitrile gradient containing a trifluoroacetic acid modifier and UV detection near 214 nm, separates the target heptapeptide from deletion sequences, truncations, and synthesis by-products. Purity is reported as the area percentage of the main peak, and research-grade material is commonly listed at 98% or higher. Mass spectrometry — electrospray ionization or MALDI-TOF — then confirms that the dominant peak actually corresponds to the calculated mass of the intended seven-residue sequence rather than a closely eluting impurity. Chromatographic purity without a matching mass spectrum is incomplete evidence, which is one reason buyers reviewing real versus counterfeit material are told to ask for both traces.

Supplementary assays may include net peptide content (the fraction of vial mass that is peptide rather than counter-ion and residual water), Karl Fischer moisture determination, and endotoxin screening when material is destined for animal work. A lot-specific chromatogram, time-stamped and tied to the vial label, is more informative than a generic document, a point covered in guidance on vetting a peptide supplier and in the compound FAQ.

What should a certificate of analysis for PE-22-28 include?

A usable certificate of analysis identifies the lot, not just the product. Expect the full amino acid sequence in one-letter or three-letter code, the molecular formula, the theoretical molecular weight, the gross vial fill, the test date, and the name of the laboratory that performed the analysis. The analytical section should carry an HPLC chromatogram with retention time and integrated peak areas, plus a mass spectrum showing the observed versus calculated mass. Appearance (white to off-white lyophilized powder), moisture content, and counter-ion identity are frequently included and are useful when comparing lots over time.

Red flags are mundane: no lot number, an undated report, a chromatogram with the axes cropped, or identical documents reused across different products. Independent third-party verification carries more weight than an in-house sheet alone, a distinction examined in material on distinguishing authentic from substandard supply and in the broader checklist for assessing supplier legitimacy. Because this compound is sold strictly for laboratory use, the certificate should also carry research-use-only language consistent with its regulatory classification. Buyer-side commentary collected in vendor reviews often turns on exactly these documentation details.

How should lyophilized PE-22-28 be stored in a laboratory setting?

Lyophilized peptide powder is the most stable form this compound takes. Standard practice for short-chain synthetic peptides is storage at −20 °C or colder in a sealed, light-protected vial, kept dry with desiccant and allowed to equilibrate to room temperature before the seal is broken so that atmospheric moisture does not condense onto cold powder. Peptides are hygroscopic; absorbed water accelerates hydrolysis and can promote aggregation over long periods. Brief excursions to refrigerator temperature during handling are generally tolerated, but repeated warm-cold cycling is the variable most often blamed for lot-to-lot drift in long-running laboratory inventories.

Material held in solution is considerably less stable than the dry powder, which is why most laboratories plan their stock around the lyophilized form and keep working aliquots small and single-use. Freeze-thaw cycles should be minimized and logged. Detailed handling considerations are laid out in the storage and stability reference, and the narrower question of whether cold storage is strictly required at every stage is addressed in the refrigeration discussion. Conditions during transit matter as much as conditions on arrival, a topic covered under cold-chain handling.

Does PE-22-28 require cold-chain shipping, and what happens in transit?

Short synthetic peptides in lyophilized form are comparatively robust during shipping. The powder tolerates limited time at ambient temperature, which is why many suppliers ship with insulated packaging and a gel pack rather than dry ice. The practical risks in transit are moisture ingress through a compromised stopper, physical damage to the vial, and prolonged exposure to heat in a delivery vehicle or on a loading dock. Vials that arrive with powder visibly caked, discolored, or shifted from the vial base are worth documenting before anything else happens to them.

On receipt, laboratories typically log the arrival temperature, confirm that lot numbers on the vial and certificate match, and move the material straight to long-term cold storage. Customs handling and delivery delays are the main variables outside the supplier's control, and they are more common on international routes; buyers searching for regional availability often do so specifically to shorten transit time. Packaging standards and what to inspect at the door are detailed in the shipping and cold-chain guide, while the interaction between transit temperature and shelf life is discussed alongside refrigeration requirements and the general stability reference.

Is PE-22-28 approved by any regulatory agency or scheduled as a controlled substance?

No. PE-22-28 has no marketing authorization from the FDA, the EMA, or any comparable national regulator, and it is not an approved drug product in any jurisdiction. It is also not recognized as a dietary ingredient or food additive, and it is not sold as a compounded preparation. Material in circulation is supplied as a research chemical, labeled for laboratory and in vitro or animal investigational use only, and that labeling is the legal basis on which it is distributed. The compound is not listed on international controlled-substance schedules, but absence from a schedule is not the same thing as approval — it simply means the compound has never been through the review that would place it in either category.

Import rules, state-level provisions, and courier policies vary, and research chemicals occasionally attract scrutiny at customs even when nothing is scheduled. The current picture is summarized in the FDA status overview and the broader legal status discussion. Because the safety record rests entirely on preclinical work, the evidence-based safety analysis and the contraindications and safety profile reference are the relevant companion reading rather than any approval document.

How can a laboratory tell authentic PE-22-28 from mislabeled or counterfeit material?

Visual inspection gets you very little. Lyophilized peptides generally look alike — white to off-white, sometimes a thin film rather than a fluffy cake — and bulking agents such as mannitol can make an underfilled vial look generously filled. The reliable checks are analytical: a lot-matched HPLC chromatogram and a mass spectrum whose observed mass matches the calculated mass for the seven-residue sequence. Where stakes are high, laboratories send an aliquot for independent confirmation, since a counterfeit will usually fail mass confirmation outright or show a main peak at the wrong retention time.

Documentation patterns are the second tell. Reused certificates, missing lot numbers, purity claims with no supporting trace, and vials whose labels do not match the paperwork all point the same direction. Supplier-side diligence — company history, consistency of analytical partners, willingness to supply raw data — is covered in the guide to identifying a legitimate supplier, while the analytical side is expanded in the authenticity comparison. Community reporting aggregated in forum and review analysis is anecdotal but occasionally surfaces supply problems early, and several widespread misconceptions are untangled in the myths discussion.

What downstream signaling does TREK-1 inhibition actually engage?

TREK-1 is a two-pore-domain potassium channel (KCNK2) that produces a background outward current, helping set resting membrane potential in neurons of the dorsal raphe, hippocampus, prefrontal cortex, and elsewhere. Blocking that leak current is expected to depolarize the cell and lower the threshold for firing. In serotonergic raphe neurons, that translates into altered firing rates and downstream changes in serotonergic tone. Genetic work established the channel's relevance to mood-related behavior before any peptide blocker existed: mice lacking TREK-1 showed a depression-resistant behavioral phenotype (PMID 16633341 (PubMed PMID 16633341)), and the sortilin-derived peptide spadin was subsequently characterized as a TREK-1 blocker with antidepressant-like activity in rodents (PMID 20405604 (PubMed PMID 20405604)).

Downstream of membrane excitability, rodent studies in this area have examined BDNF signaling, CREB phosphorylation, mTOR-related pathways, and hippocampal neurogenesis markers as candidate mediators. These are correlative readouts in animal tissue, not established mechanisms in humans. The channel pharmacology itself is detailed in the TREK-1 pharmacology overview and the channel guide, with transcriptional readouts covered under gene expression mechanisms and the pathway map in the signaling pathway reference.

Why is PE-22-28 grouped with rapid-acting antidepressant research?

The grouping is mechanistic rather than clinical. Conventional monoamine reuptake inhibitors act on transporters and, in animal models, require sustained exposure before behavioral changes appear. Compounds that work through ion channels or glutamatergic receptors — the ketamine literature being the best-known example — produce behavioral changes in rodent assays on a much shorter timescale, and that difference is what put potassium-channel blockers into the same conversation. Blocking a background leak current changes neuronal excitability immediately, so the pharmacodynamic ceiling is not set by receptor downregulation over weeks.

What that means in practice is unsettled. Rodent behavioral assays such as the forced swim and tail suspension tests are screening tools with well-documented limitations, and a fast readout in those paradigms does not predict a fast clinical effect. No peptide in this family has an approval or a completed late-stage human program, so comparisons between animal timelines and human expectations remain speculative. The mechanistic case is laid out in the rapid-acting antidepressant overview and the more detailed onset mechanism analysis, while the translational gap between species is examined directly in the animal versus human research comparison and in the depression mechanism studies review.

Why do researchers study PE-22-28 alongside other peptides?

Combination work in preclinical neuroscience is usually about isolating mechanism, not about compounding effects. If a TREK-1 blocker and a compound acting through a different target produce overlapping behavioral readouts in rodents, running them together — and separately — helps determine whether the pathways converge, interfere, or operate independently. Peptides with GABAergic or neurotrophic profiles are common comparators for this reason, which is why PE-22-28 appears in head-to-head discussions with compounds such as Selank rather than only in isolation.

The methodological caveats are substantial. Multi-compound animal studies multiply confounds, make attribution of any observed change harder, and introduce pharmacokinetic questions that single-agent work avoids. Published data on combinations involving this specific heptapeptide are limited, so most of what circulates is extrapolation from single-agent rodent studies plus mechanistic reasoning. Framework considerations for designing such comparisons are outlined in the research combinations guide and the combined peptides discussion. Known and theoretical pharmacological overlaps are catalogued under interactions researchers should know, and the direct mechanistic contrast with a widely studied alternative is covered in the Selank comparison.